Thromboelastography Parameters do not Discriminate for Thrombotic Events in Hospitalized Patients With COVID-19.


Journal

Journal of intensive care medicine
ISSN: 1525-1489
Titre abrégé: J Intensive Care Med
Pays: United States
ID NLM: 8610344

Informations de publication

Date de publication:
May 2023
Historique:
medline: 4 4 2023
pubmed: 1 12 2022
entrez: 30 11 2022
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state; leading to multiple sequelae. We sought to detect whether thromboelastography (TEG) parameters would be able to detect thromboembolic events in patients hospitalized with COVID-19. We performed a retrospective multicenter case-control study of the Collaborative Research to Understand the Sequelae of Harm in COVID (CRUSH COVID) registry of 8 tertiary care level hospitals in the United States (US). This registry contains adult patients with COVID-19 hospitalized between March 2020 and September 2020. A total of 277 hospitalized COVID-19 patients were analyzed to determine whether conventional coagulation TEG parameters were associated with venous thromboembolic (VTE) and thrombotic events during hospitalization. A clotting index (CI) >3 was present in 45.8% of the population, consistent with a hypercoagulable state. Eighty-three percent of the patients had clot lysis at 30 min (LY30)  =  0, consistent with fibrinolysis shutdown, with a median of 0.1%. We did not find TEG parameters (LY30 area under the receiver operating characteristic [ROC] curve [AUC]  =  0.55, 95% CI: 0.44-0.65, In this retrospective multicenter cohort study, TEG in COVID-19 hospitalized patients may indicate a hypercoagulable state, however, its use in detecting VTE or thrombotic events is limited in this population.

Sections du résumé

BACKGROUND BACKGROUND
Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state; leading to multiple sequelae. We sought to detect whether thromboelastography (TEG) parameters would be able to detect thromboembolic events in patients hospitalized with COVID-19.
METHODS METHODS
We performed a retrospective multicenter case-control study of the Collaborative Research to Understand the Sequelae of Harm in COVID (CRUSH COVID) registry of 8 tertiary care level hospitals in the United States (US). This registry contains adult patients with COVID-19 hospitalized between March 2020 and September 2020.
RESULTS RESULTS
A total of 277 hospitalized COVID-19 patients were analyzed to determine whether conventional coagulation TEG parameters were associated with venous thromboembolic (VTE) and thrombotic events during hospitalization. A clotting index (CI) >3 was present in 45.8% of the population, consistent with a hypercoagulable state. Eighty-three percent of the patients had clot lysis at 30 min (LY30)  =  0, consistent with fibrinolysis shutdown, with a median of 0.1%. We did not find TEG parameters (LY30 area under the receiver operating characteristic [ROC] curve [AUC]  =  0.55, 95% CI: 0.44-0.65,
CONCLUSIONS CONCLUSIONS
In this retrospective multicenter cohort study, TEG in COVID-19 hospitalized patients may indicate a hypercoagulable state, however, its use in detecting VTE or thrombotic events is limited in this population.

Identifiants

pubmed: 36448250
doi: 10.1177/08850666221142265
pmc: PMC9713537
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

449-456

Auteurs

Susan Kartiko (S)

Department of Surgery, 43989George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Naoru Koizumi (N)

43989George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
George Mason University, Schar School of Policy and Government, Fairfax, VA, USA.

David Yamane (D)

Department of Emergency Medicine, Anesthesiology and Critical Care Medicine, 43989George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Babak Sarani (B)

Department of Surgery, 43989George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Abu B Siddique (AB)

George Mason University, Schar School of Policy and Government, Fairfax, VA, USA.

Andrea R Levine (AR)

Division of Pulmonary and Critical Care, Department of Medicine, 12264University of Maryland School of Medicine, Baltimore, MD, USA.

Amanda M Jackson (AM)

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Madigan Army Medical Center, Joint Base Lewis-McChord, WA, USA.

Patrick M Wieruszewski (PM)

Departments of Anesthesiology and Pharmacy, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA.

Nathan J Smischney (NJ)

Department of Anesthesiology and Perioperative Medicine, Division of Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.

Ashish K Khanna (AK)

Department of Anesthesiology, Section on Critical Care Medicine, Wake Forest School of Medicine, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Outcomes Research Consortium, Cleveland, OH, USA.

Jonathan H Chow (JH)

Department of Anesthesiology and Critical Care Medicine, 43989George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH